Literature DB >> 11166238

Model Systems: transgenic mouse models for measles pathogenesis.

M Manchester1, G F Rall.   

Abstract

Studies of the diseases caused by measles virus (MV) in humans have been restricted owing to the lack of suitable animal models. The discovery of cellular receptors for MV entry has facilitated the development of transgenic mice that are susceptible to MV infection, and that mimic certain aspects of the central nervous system diseases and immunosuppression that can occur in infected humans. Moreover, such mouse models have allowed a clearer understanding of the contributions of the innate and adaptive immune response following infection, and will no doubt be important tools in the future for the development of new antiviral and vaccine reagents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166238     DOI: 10.1016/s0966-842x(00)01903-x

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  16 in total

1.  T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue.

Authors:  Samantha R Stubblefield Park; Mi Widness; Alan D Levine; Catherine E Patterson
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Emerging roles and new functions of CD46.

Authors:  M Kathryn Liszewski; Claudia Kemper; Jeffrey D Price; John P Atkinson
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.

Authors:  Caroline I Sellin; Nathalie Davoust; Vanessa Guillaume; Dominique Baas; Marie-Françoise Belin; Robin Buckland; T Fabian Wild; Branka Horvat
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.

Authors:  Sangeet Lal; Diego Carrera; Joanna J Phillips; William A Weiss; Corey Raffel
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

Review 5.  Potential and clinical translation of oncolytic measles viruses.

Authors:  Steven Robinson; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2017-03       Impact factor: 4.388

Review 6.  Making it to the synapse: measles virus spread in and among neurons.

Authors:  V A Young; G F Rall
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 7.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

8.  Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

Authors:  R M Myers; S M Greiner; M E Harvey; G Griesmann; M J Kuffel; S A Buhrow; J M Reid; M Federspiel; M M Ames; D Dingli; K Schweikart; A Welch; A Dispenzieri; K-W Peng; S J Russell
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

9.  Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection.

Authors:  Mark K Slifka; Dirk Homann; Antoinette Tishon; Robb Pagarigan; Michael B A Oldstone
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells.

Authors:  Hila Naaman; Tatiana Rabinski; Avi Yizhak; Solly Mizrahi; Yonat Shemer Avni; Ran Taube; Bracha Rager; Yacov Weinstein; Glenn Rall; Jacob Gopas; Rivka Ofir
Journal:  Cell Reprogram       Date:  2018-02       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.